| Literature DB >> 28635952 |
Matthew A Lines1,2, Yoko Ito1,2, Kristin D Kernohan1,2, Wendy Mears1, Julie Hurteau-Miller2,3, Sunita Venkateswaran2,4, Leanne Ward2,5, Karine Khatchadourian2,5, Jeff McClintock6, Priya Bhola2,7, Philippe M Campeau8,9, Kym M Boycott1,2, Jean Michaud2,6, André Bp van Kuilenburg10, Sacha Ferdinandusse10, David A Dyment1,2,11.
Abstract
Yunis-Varón syndrome (YVS) is an autosomal recessive disorder comprising skeletal anomalies, dysmorphism, global developmental delay and intracytoplasmic vacuolation in brain and other tissues. All hitherto-reported pathogenic variants affect FIG4, a lipid phosphatase involved in phosphatidylinositol (3,5)-bisphosphate [PtdIns(3,5)P2] metabolism. FIG4 interacts with PIKfyve, a lipid kinase, via the adapter protein VAC14; all subunits of the resulting complex are essential for PtdIns(3,5)P2 synthesis in the endolysosomal membrane compartment. Here, we present the case of a female neonate with clinical features of YVS and normal FIG4 sequencing; exome sequencing identified biallelic rare coding variants in VAC14. Cultured patient fibroblasts exhibited a YVS-like vacuolation phenotype ameliorated in a dose-dependent fashion by ML-SA1, a pharmacological activator of the lysosomal PtdIns(3,5)P2 effector TRPML1. The patient developed a diffuse leukoencephalopathy with loss of the normal N-acetylaspartate spectrographic peak and presence of a large abnormal peak consistent with myoinositol. We report that VAC14 is a second gene for Yunis-Varón syndrome.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28635952 PMCID: PMC5558182 DOI: 10.1038/ejhg.2017.99
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246